RXR-alpha variant-targeting agent NM6603

{
  "id": "MLC-T-ONC-016610",
  "term": "RXR-alpha variant-targeting agent NM6603",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable small molecule agent that targets retinoid X receptor alpha (RXR-alpha; RXRA) variant, with potential antineoplastic activity. Upon oral administration, RXR-alpha variant-targeting agent NM6603 selectively targets and binds to RXR-alpha variants and inhibits transforming growth factor-beta (TGFb)-mediated signaling pathway. This abrogates TGF-beta-mediated immunosuppression in the tumor microenvironment (TME), increases cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. RXR-alpha, a transcription factor that plays an important role in the regulation of the expression of multiple genes, is often modified in various types of tumor cells.",
  "synonyms": [
    "retinoid X receptor alpha variant-targeting agent NM6603",
    "RXRA variant-targeting agent NM6603"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rxr-alpha-variant-targeting-agent-nm6603/"
}